AR and prostate carcinoma: In hormone‐dependent cancers, such as prostate and breast cancer, LXR also acts by regulating hormone metabolism, such as antagonism of androgen receptor signaling [39], upregulation of sulphotransferase 2A1, and downregulation of steroid sulphatase to inactivate androgen in prostate cancer [40], and reduction of the expression of estrogen receptor α in breast cancer [34, 41].